BBOT
Price:
$11.54
Market Cap:
$923.07M
BridgeBio Oncology Therapeutics is a clinical-stage biopharmaceutical company developing next-generation small molecule therapeutics targeting RAS and PI3Kα malignancies, which are prevalent oncogenes in human tumors. Initially formed as a subsidiary of BridgeBio Pharma, it focuses on precision oncology with a pipeline that includes BBO-8520, BBO-10203, and BBO-11818 programs targeting KRAS and PI3K pathways. The company recently went public through a business combination with Helix Acquisition Corp. II, raising approximately $450 million to advance clinical development. The CEO is Dr. Eli Wallace, and the CSO is Dr. Pedro Beltran.
Industry
Biotechnology
IPO Date
2025-08-12
Stock Exchange
NASDAQ
Ticker
BBOT
According to BridgeBio Oncology Therapeutics Inc.’s latest financial reports and current stock price. The company's current ROE is -77.14%. This represents a change of 1.47% compared to the average of -4.92% of the last 4 quarters.
The mean historical ROE of BridgeBio Oncology Therapeutics Inc. over the last ten years is 25.50%. The current -77.14% ROE has changed -100.30% with respect to the historical average. Over the past ten years (40 quarters), BBOT's ROE was at its highest in in the December 2023 quarter at 65.59%. The ROE was at its lowest in in the June 2024 quarter at -11.84%.
Average
25.50%
Median
126.14%
Minimum
-39.36%
Maximum
101.78%
Discovering the peaks and valleys of BridgeBio Oncology Therapeutics Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 632.45%
Maximum Annual ROE = 101.78%
Minimum Annual Increase = -100.04%
Minimum Annual ROE = -39.36%
| Year | ROE | Change |
|---|---|---|
| 2024 | -39.36% | -100.04% |
| 2023 | 101.78% | 632.45% |
| 2022 | 16.09% | -93.19% |
The current ROE of BridgeBio Oncology Therapeutics Inc. (BBOT) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
33.92%
5-year avg
25.50%
10-year avg
25.50%
BridgeBio Oncology Therapeutics Inc.’s ROE is greater than Mind Medicine (MindMed) Inc. (-86.18%), less than UroGen Pharma Ltd. (503.46%), greater than Nurix Therapeutics, Inc. (-53.57%), greater than Xencor, Inc. (-26.73%), greater than Kodiak Sciences Inc. (-176.58%), greater than AnaptysBio, Inc. (-1101.24%), less than Phathom Pharmaceuticals, Inc. (77.32%), greater than Oculis Holding AG (-90.60%), greater than Tango Therapeutics, Inc. (-79.72%), greater than Septerna, Inc. (-14.83%),
| Company | ROE | Market cap |
|---|---|---|
| -86.18% | $939.13M | |
| 503.46% | $1.14B | |
| -53.57% | $1.39B | |
| -26.73% | $1.30B | |
| -176.58% | $1.31B | |
| -1101.24% | $1.20B | |
| 77.32% | $1.05B | |
| -90.60% | $1.03B | |
| -79.72% | $1.09B | |
| -14.83% | $1.17B |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like BridgeBio Oncology Therapeutics Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like BridgeBio Oncology Therapeutics Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is BridgeBio Oncology Therapeutics Inc.'s ROE?
How is the ROE calculated for BridgeBio Oncology Therapeutics Inc. (BBOT)?
What is the highest ROE for BridgeBio Oncology Therapeutics Inc. (BBOT)?
What is the 3-year average ROE for BridgeBio Oncology Therapeutics Inc. (BBOT)?
What is the 5-year average ROE for BridgeBio Oncology Therapeutics Inc. (BBOT)?
How does the current ROE for BridgeBio Oncology Therapeutics Inc. (BBOT) compare to its historical average?